Isotretinoin for acne

Reading File

Finding Sources

Searching PubMed

isotretinoin acne treatment

Reading File

I now have enough comprehensive data. Here is the full evidence-based summary:

Isotretinoin for Acne

Overview

Isotretinoin (13-cis-retinoic acid) is a synthetic vitamin A derivative and the most effective medication available for acne. It was available in Europe from 1971 and FDA-approved in the US in 1982. It remains the only drug that targets all four major pathogenic factors in acne: sebum production, follicular keratinization, bacterial colonization, and inflammation.

Dermatology 2-Volume Set 5e, p. 731: "The introduction of oral isotretinoin was a key advance in acne therapy and it still remains the most effective medication."

Indications

Severe, nodulocystic acne (FDA-approved indication)
Significant acne resistant to oral antibiotics
Acne with rapid relapse after treatment
Acne causing scarring (physical or emotional)
Gram-negative folliculitis
Pyoderma faciale
Acne fulminans (with low-dose oral corticosteroid to prevent flare)

Mechanism of Action

The exact mechanism is not fully understood but includes:

Sebaceous gland suppression - the most significant initial effect; profound inhibition of sebaceous gland size and sebum output
Reduction of C. acnes (P. acnes) - indirect, via decreased intrafollicular lipids needed for bacterial growth (no direct in vitro activity)
Normalization of follicular keratinization - reduces abnormal desquamation and comedone formation
Anti-inflammatory effects

Notably, sebum production returns to normal after 2-4 months in most patients, yet long-term remissions persist - the mechanism for this durable response remains unclear.

Dosing

Phase	Dose
Month 1 (initiation)	0.5 mg/kg/day (reduces initial flare risk)
Months 2-5+	0.5-1 mg/kg/day with fatty meal
Severe/scarring disease	Up to 2 mg/kg/day
Target cumulative dose	120-150 mg/kg (reduces relapse risk)
Moderate acne (lower-dose regimen)	0.25-0.4 mg/kg/day for 6 months (40-70 mg/kg cumulative)

Lidose-isotretinoin (Absorica) can be taken without food due to improved absorption.
Treatment typically continues 1-3 months after complete clearance.
~95% of patients achieve a good clinical response after 20 weeks.

Adverse Effects

Skin and Mucous Membranes (most common, dose-dependent)

Cheilitis - virtually universal
Xerosis, dry mucous membranes (>50% of patients)
Skin fragility, eczematous eruption
Excess granulation tissue, paronychia
Staphylococcus aureus skin infections

Eyes

Xerophthalmia, conjunctivitis, keratitis, night blindness
Corneal opacities (rare)

Musculoskeletal

Myalgias, low back pain, arthralgias
Elevated creatine kinase / rhabdomyolysis (more common in athletes)
Skeletal hyperostosis with long-term use; premature epiphyseal closure in children

Metabolic / Lab

Triglycerides and/or cholesterol elevated in 20-50% of patients
Mild transaminase elevation (occasional)
Severe elevations requiring dose modification are rare

Neurological

Pseudotumor cerebri (benign intracranial hypertension) - presents with headache, nausea, visual changes. Do not combine with tetracyclines (additive risk).
Headache, fatigue, lethargy

Psychiatric

Depression, suicidal ideation, and psychosis are listed as possible side effects, but meta-analyses have not confirmed a causal link. Current evidence suggests acne treatment actually decreases depression prevalence. Monitoring is still recommended.

GI

Current data do not support an association with inflammatory bowel disease.

Teratogenicity (Category X)

Causes severe congenital malformations (craniofacial, cardiac, CNS)
See iPLEDGE requirements below

iPLEDGE Program (US)

Mandatory FDA Risk Evaluation and Mitigation Strategy (REMS):

Physicians, pharmacists, and patients must all register
All patients: monthly office visits and counseling
Patients with childbearing potential:
- 2 negative pregnancy tests before starting
- Effective contraception for 1 month before, during, and 1 month after treatment
- Monthly pregnancy testing during therapy
Counsel patients not to share medication

Monitoring

Parameter	Timing
Pregnancy test (x2)	Before initiation
Lipids (fasting TG, cholesterol)	Baseline, then within first 2 months
LFTs	Baseline, periodically
CBC	Baseline (as needed)
Monthly pregnancy test	Every visit (if childbearing potential)

Relapse and Retreatment

~1/3 of patients require a second course
Risk factors for relapse: male sex, young age, short treatment duration, low cumulative dose, PCOS in women
Maintenance with a topical retinoid ± benzoyl peroxide after completing isotretinoin may reduce recurrence
A second course may be initiated 2 months after the first, if severe cystic acne persists

Initial Flare

Flare during month 1 is common, especially with macrocomedones or high starting doses
Rare but serious: isotretinoin-induced acne fulminans (more frequent in adolescent boys) - manage with reduced dose + low-dose oral corticosteroid

Special Notes

Acne scarring and sinus tracts do not respond to isotretinoin; surgical management is needed for these
Combining isotretinoin with energy-based devices (laser/light) is an emerging area - a 2025 meta-analysis (PMID: 39509291) found combination therapy may improve outcomes over isotretinoin alone

Sources: Dermatology 2-Volume Set 5e (Elsevier), p. 731 | Fitzpatrick's Dermatology, p. 1437 | Katzung's Basic and Clinical Pharmacology 16e, p. 1677

Is 20 mg per day for 1 month enough to entirely stop my acne

Short answer: almost certainly not, for two reasons — the dose is too low and the duration is too short.

Why 20 mg/day for 1 month is insufficient

Dose is likely too low

Standard isotretinoin dosing is 0.5–1 mg/kg/day. For a 20 mg/day dose to be appropriate, you would need to weigh around 20–40 kg (44–88 lbs). For most adults, 20 mg/day falls well below the therapeutic dose range.

Duration is far too short

The most important number in isotretinoin treatment is the cumulative dose, not the daily dose. The evidence-based target is 120–150 mg/kg total to meaningfully reduce relapse risk.

For example, if you weigh 70 kg:

Target cumulative dose: ~8,400–10,500 mg total
20 mg/day × 30 days = 600 mg total — roughly 6–7% of what's needed

What actually happens at 1 month

Month 1 is typically when the initial flare occurs — acne can temporarily worsen before it improves
Sebaceous gland suppression is building but incomplete
Clearance typically takes 20 weeks (5 months) at standard doses

What sub-therapeutic courses tend to produce

Temporary partial improvement while on the drug
Relapse within weeks to months of stopping — often back to baseline or worse
You'd need to restart, and short prior courses are a predictor of treatment failure

The practical reality

A course like this (low dose, 1 month) is sometimes used as a starting ramp to minimize the initial flare — but it is never used as a standalone complete treatment. It must be followed by continued dosing at weight-appropriate levels for a total of 4–6+ months.

Bottom line: 20 mg/day for 1 month will not stop your acne long-term. The dose needs to be matched to your weight (0.5–1 mg/kg/day) and continued until you reach a cumulative dose of 120–150 mg/kg, which takes months. Talk to your prescribing doctor about whether your current regimen is correctly calibrated for your weight and severity of disease.

Hair related side effects

Finding Sources

Searching PubMed

isotretinoin alopecia hair loss

Reading File

Here is what the textbooks say specifically about isotretinoin and hair:

Isotretinoin: Hair-Related Side Effects

The main effect: Telogen Effluvium

The primary hair side effect is diffuse hair loss caused by telogen effluvium - isotretinoin shifts hair follicles prematurely into the resting (telogen) phase, causing shedding diffusely across the scalp several weeks after the trigger.

Key facts from the literature:

It is a relatively common complaint - many patients notice increased shedding
Objective (visible) alopecia tends to occur only at higher dose levels and after several months of therapy
The hair loss is typically diffuse, not patterned
It is less severe with isotretinoin than with acitretin (another oral retinoid used for psoriasis), which causes more significant alopecia

Is it permanent?

No. Telogen effluvium from isotretinoin is reversible. Hair typically regrows after stopping the drug. The follicles are not destroyed - they are just temporarily pushed into a resting state.

Dose relationship

Hair loss is dose-dependent:

At standard acne doses (0.5-1 mg/kg/day), noticeable shedding can occur but frank alopecia is uncommon
Clinically significant hair thinning is more likely at higher doses or with prolonged courses

Why it happens

Isotretinoin reduces sebum production and affects the hair follicle's cycling. The sebaceous gland is closely linked to follicle function, and retinoids broadly affect epithelial growth and differentiation - this includes the follicular epithelium.

Other hair/scalp-related effects

Nail apparatus changes often accompany the hair effects: nail thinning, nail fragility, nail plate shedding, and paronychia-like periungual granulation tissue
Scalp xerosis/dryness - the same mechanism causing skin and lip dryness also affects the scalp

Practical Implications

Question	Answer
Will I lose hair?	Shedding is a common complaint; visible thinning is less common
When does it start?	Typically after several months of therapy
Is it permanent?	No - reverses after stopping
What reduces the risk?	Lower cumulative doses; some evidence for omega-3/vitamin E supplementation (nutraceuticals) as adjuncts
Should I stop treatment?	Not usually - discuss with your doctor if severe

A 2024 systematic review in JAAD (PMID 37871802) examined oral nutraceuticals as adjuncts to reduce isotretinoin side effects, including hair loss, though the evidence base for specific supplements remains limited. If hair shedding is a concern, raise it with your prescriber before or at the start of treatment.

Dermatology 2-Volume Set 5e, p. 977 | Fitzpatrick's Dermatology, p. 3432

This is a shared conversation. Sign in to Orris to start your own chat.